{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:12:23Z","timestamp":1788628343778,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-1 (IL-1)\u2013mediated inflammation can contribute to lung injury, impaired alveolar development, and pulmonary vascular dysfunction in critically ill neonates. Anakinra, a recombinant IL-1 receptor antagonist, has emerged as a potential adjunct therapy in severe neonatal hyperinflammatory and respiratory conditions, but evidence in this population remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of 15 neonates treated off label with anakinra (10\u2005mg\/kg\/day in two doses) at a tertiary neonatal intensive care unit between 2021 and 2025. Clinical indications included severe or evolving bronchopulmonary dysplasia (BPD), secondary hemophagocytic lymphohistiocytosis (HLH), pulmonary hypertension, interstitial lung disease and complex congenital anomalies. Respiratory support was evaluated at treatment initiation and at predefined follow-up timepoints up to 60 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 73% of infants required mechanical ventilation and 27% non-invasive ventilation. By the end of treatment (data available for 14\/15 infants), mechanical ventilation decreased to 21% (absolute reduction 52%, relative reduction 71%), while spontaneous breathing with or without supplemental oxygen increased to 64%. All infants survived. Anakinra was generally well tolerated: transient transaminase elevations occurred in 40%, \u03b3GT increases in 20%, and transient neutropenia in 13%, with no clinically significant hepatotoxicity, allergic reactions, or seizures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this largest neonatal cohort to date, Anakinra administration was associated with improvements in respiratory status, although a direct causal relationship cannot be established, and a favorable safety profile. Multicenter randomized controlled trials are warranted to confirm these findings, especially in preterm infants at risk of developing bronchopulmonary dysplasia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1806329","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:41Z","timestamp":1778823761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Respiratory effects of off label anakinra in critically ill neonates: a 15-patient observational cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Domenico Umberto","family":"De Rose","sequence":"first","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia Maria","family":"Cesaroni","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Campi","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maddaloni","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ronci","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caoci","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Capolupo","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dotta","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, \u201cBambino Ges\u00f9\u201d Children's Hospital IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study","volume":"37","author":"Sota","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X20959575","article-title":"The off-label use of anakinra in pediatric systemic autoinflammatory diseases","volume":"12","author":"Maniscalco","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40272-024-00679-x","article-title":"Off-label use of anakinra in inflammatory conditions in neonates and infants up to 3 months of age: a case series and a review of the literature","volume":"27","author":"De Rose","year":"2025","journal-title":"Paediatr Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.1022104","article-title":"Anakinra Pilot\u2014a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants","volume":"13","author":"Green","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/iid3.548","article-title":"Anakinra reduces lung inflammation in experimental acute lung injury","volume":"10","author":"Engeroff","year":"2022","journal-title":"Immunity Inflamm Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"L49","DOI":"10.1152\/ajplung.00060.2019","article-title":"Infants with evolving bronchopulmonary dysplasia demonstrate monocyte-specific expression of IL-1 in tracheal aspirates","volume":"317","author":"Eldredge","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3390\/ijms24032795","article-title":"The role of the interleukin-1 family in complications of prematurity","volume":"24","author":"Green","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00281-020-00803-2","article-title":"Preterm birth and sustained inflammation: consequences for the neonate","volume":"42","author":"Humberg","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41372-025-02275-4","article-title":"Dynamic association between plasma interleukin-1 family concentrations and bronchopulmonary dysplasia in extremely premature infants","volume":"46","author":"Li","year":"2026","journal-title":"J Perinatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14384","DOI":"10.1073\/pnas.1306859110","article-title":"Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia","volume":"110","author":"Nold","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01480","article-title":"Interleukin-1 receptor antagonist protects newborn mice against pulmonary hypertension","volume":"10","author":"Bui","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1159\/000540002","article-title":"BPD: latest strategies of prevention and treatment","volume":"121","author":"Durlak","year":"2024","journal-title":"Neonatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"823847","DOI":"10.3389\/fped.2022.823847","article-title":"Anakinra in paediatric rheumatology and periodic fever clinics: is the higher dose safe?","volume":"10","author":"Fingerhutov\u00e1","year":"2022","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/1673-5374.341044","article-title":"Interleukin-1: an important target for perinatal neuroprotection?","volume":"18","author":"Kelly","year":"2023","journal-title":"Neural Regen Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1806329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:42Z","timestamp":1778823762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1806329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":18,"alternative-id":["10.3389\/fped.2026.1806329"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1806329","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1806329"}}